|Articles|May 15, 2020

AJMC® in the Press, May 15, 2020

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A piece by HealthTech, titled “6 Reasons Telehealth Is Now More Important Than Ever,” referenced an article published on AJMC.com, the website of The American Journal of Managed Care^®. The article, “Pandemic Brings Racial, Economic Healthcare Disparities Into Focus,” highlighted how the coronavirus disease 2019 (COVID-19) pandemic is slowly seeping into the nation’s economically vulnerable populations and is already taking a toll on minority communities.

An op-ed posted on The Daily Star cited an article published on AJMC.com, titled “How Has COVID-19 Affected Mental Health, Severity of Stress Among Employees?” The article highlighted findings of a recent survey by mental health provider Ginger, which reported that nearly 7 in 10 employees think the COVID-19 pandemic is the most stressful time of their entire professional career.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

MCL | Image Credit: Zhanna - stock.adobe.com

October 7th, 2026

As Mantle Cell Lymphoma Risk Tools Advance, Access Lags Behind

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

FDA approval | Image Credit: Tada Images - stock.adobe.com

October 7th, 2026

FDA Approves First Symptomatic Dermographism Treatment

Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.

Hip bone density deficits in leukemia survivors were smaller with longer time since diagnosis in lower-risk groups but not after high-risk ALL therapy. | Image credit: yurakrasil - stock.adobe.com

October 7th, 2026

Hip Bone Density Deficits Persist in High-Risk ALL Survivors

Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.

Close up of Retatrutide Glass Vial and Single Use Insulin Syringes | Image credit: Anna Hoychuk - stock.adobe.com

October 7th, 2026

5 Things to Know if Retatrutide Is Classified as a Biologic

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

person touching lower back - Pormezz - stock.adobe.com

October 7th, 2026

Sacral Neuromodulation Still Seen as OAB Gold Standard in Review

Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.

Tucatinib now has FDA approval as a frontline maintenance option in HER2+ metastatic breast cancer, with a label boxed warning for severe hepatotoxicity. | Image Credit: BHM - stock.adobe.com

October 7th, 2026

FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer

FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.